These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 12775677

  • 1. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG, DeCorby M, Noreddin A, Mendoza C, Cumming A, Nichol K, Wierzbowski A, Hoban DJ.
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [Abstract] [Full Text] [Related]

  • 2. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
    Sevillano D, Alou L, Aguilar L, Echevarría O, Giménez MJ, Prieto J.
    J Antimicrob Chemother; 2006 Jun; 57(6):1128-33. PubMed ID: 16617063
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG, Johanson C, Hisanaga T, Mendoza C, Laing N, Noreddin A, Wierzbowski A, Hoban DJ.
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG, Johanson C, Laing N, Hisanaga T, Wierzbowski A, Hoban DJ.
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations.
    Noreddin AM, Roberts D, Nichol K, Wierzbowski A, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2002 Dec; 46(12):4029-34. PubMed ID: 12435719
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
    Alou L, Giménez MJ, Sevillano D, Aguilar L, Cafini F, Echeverría O, Pérez-Trallero E, Prieto J.
    J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
    [Abstract] [Full Text] [Related]

  • 9. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
    Wierzbowski AK, Nichol K, Laing N, Hisanaga T, Nikulin A, Karlowsky JA, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
    [Abstract] [Full Text] [Related]

  • 10. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA, Ariano RE, Iacovides H, Sun S, Harding GK.
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [Abstract] [Full Text] [Related]

  • 11. Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: a pharmacodynamic in vitro model approach to selection of resistant populations.
    Sevillano D, Aguilar L, Alou L, Giménez MJ, Echevarría O, Cafini F, Valero E, Fenoll A, Prieto J.
    J Antimicrob Chemother; 2006 Oct; 58(4):794-801. PubMed ID: 16880173
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I, Cars O, Löwdin E.
    J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [Abstract] [Full Text] [Related]

  • 19. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
    Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J.
    J Antimicrob Chemother; 2004 Dec; 54(6):1148-51. PubMed ID: 15489246
    [Abstract] [Full Text] [Related]

  • 20. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, Firsov AA.
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.